PT-141 vs Melanotan II
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and Melanotan II (MT-2). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | Melanotan II MT-2, Melanotan 2 |
|---|---|---|
| FDA Status | FDA Approved | Not submitted |
| Category | Sexual Health | Sexual Health |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | Tanning and sexual dysfunction (research) |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $30 - $60/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 0.25-1mg 2-3x per week |
| Frequency | As needed | As needed |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | Melanocortin receptor agonist that stimulates melanogenesis for tanning and has effects on sexual arousal |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Low |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1PT-141 is FDA-approved, while Melanotan II is currently not submitted.
- 2Melanotan II is generally more affordable ($30 - $60/mo) compared to PT-141 ($800 - $1,200/mo).
- 3PT-141 has high-quality evidence, while Melanotan II has low-quality evidence.
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
Melanotan II
More budget-friendly option with lower monthly costs
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| Melanotan II | $30 - $60/mo | Not submitted | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. Melanotan II works via Melanocortin receptor agonist that stimulates melanogenesis for tanning and has effects on. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while Melanotan II costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. Melanotan II is not FDA-approved (Not submitted). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of Melanotan II include Nausea, Flushing, Spontaneous erections. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideMelanotan II is a synthetic analog of alpha-melanocyte stimulating hormone that binds to melanocortin receptors. Originally developed for skin tanning protection against UV damage, it was found to hav...
View Full Melanotan II GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and Melanotan II should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.